Roche's recent run of positive study results with giredestrant has come to an end with the failure of the persevERA trial in HR-positive, HER2-negative advanced breast cancer. The oral selective ...
Eli Lilly has positive phase 3 results for its triple agonist retatrutide in type 2 diabetes (T2D) to go with its earlier encouraging data as a weight-loss therapy. The GIP, GLP-1 and glucagon agonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results